Oliver Luxxe Assets’s Bristol-Myers Squibb BMY Stock Holding History

Oliver Luxxe Assets’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-47,067	Closed	-$2.73M	–	167
2023 Q3	$2.73M	Sell	47,067 -17,294	-27%	-$1.06M	0.7%	51
2023 Q2	$4.12M	Buy	64,361 +340	+0.5%	+$22.8K	1.03%	34
2023 Q1	$4.44M	Buy	64,021 +1,607	+3%	+$113K	1.17%	30
2022 Q4	$4.49M	Buy	62,414 +910	+1%	+$68.6K	1.25%	24
2022 Q3	$4.37M	Buy	61,504 +2,933	+5%	+$213K	1.37%	13
2022 Q2	$4.51M	Buy	+58,571	New	+$4.46M	1.33%	19
2021 Q4	–	Sell	-47,855	Closed	-$2.83M	–	200
2021 Q3	$2.83M	Buy	47,855 +13,361	+39%	+$880K	0.78%	45
2021 Q2	$2.31M	Sell	34,494 -1,214	-3%	-$79.2K	0.63%	60
2021 Q1	$2.25M	Buy	35,708 +865	+2%	+$53.8K	0.68%	54
2020 Q4	$2.26M	Sell	34,843 -15,295	-31%	-$940K	0.71%	53
2020 Q3	$3.02M	Buy	50,138 +1,391	+3%	+$83.7K	1.13%	29
2020 Q2	$2.87M	Buy	48,747 +377	+0.8%	+$22.5K	1.51%	23
2020 Q1	$2.82M	Buy	+48,370	New	+$2.96M	1.77%	15
2019 Q1	–	Sell	-39,170	Closed	-$2.04M	–	114
2018 Q4	$2.04M	Buy	39,170 +5,875	+18%	+$316K	1.37%	34
2018 Q3	$2.08M	Buy	+33,295	New	+$1.98M	1.18%	40

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Oliver Luxxe Assets's BMY Position: Q4 2023 in Review

Oliver Luxxe Assets sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 47,067 shares — an estimated $2.73M sold.

Oliver Luxxe Assets first reported a position in BMY in Q3 2018 and held it in 15 quarters. The position peaked at $4.51M in Q2 2022. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Oliver Luxxe Assets reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Oliver Luxxe Assets sold 47,067 Bristol-Myers Squibb shares in Q4 2023, an estimated $2.73M.
Oliver Luxxe Assets first reported a position in Bristol-Myers Squibb in Q3 2018 and held it in 15 quarters.
Oliver Luxxe Assets's Bristol-Myers Squibb position peaked at $4.51M in Q2 2022.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Oliver Luxxe Assets's 13F filing for Q4 2023, filed 12 Feb 2024.